Paul A. Mahon Sells 11,000 Shares of United Therapeutics Corporation (NASDAQ:UTHR) Stock

Key Points

• Paul A. Mahon, EVP of United Therapeutics Corporation, sold 11,000 shares of stock at an average price of $304.11, resulting in a total transaction of approximately $3.34 million. This sale decreased his ownership position by 23.02%.
• The company reported earnings of $6.63 per share for the last quarter, exceeding estimates and showing a 17.2% year-over-year revenue growth with a total revenue of $794.4 million.
• United Therapeutics has been rated with a consensus of "Moderate Buy" and a target price of $383.08, with multiple analysts adjusting their price targets, reflecting a mixed outlook on the stock's performance.

United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) EVP Paul A. Mahon sold 11,000 shares of United Therapeutics stock in a transaction on Thursday, July 24th. The stock was sold at an average price of $304.11, for a total transaction of $3,345,210.00. Following the sale, the executive vice president directly owned 36,781 shares of the company's stock, valued at $11,185,469.91. This represents a 23.02% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

United Therapeutics Stock Performance

UTHR traded down $1.91 on Friday, hitting $304.50. 310,921 shares of the company were exchanged, compared to its average volume of 372,488. The stock's fifty day moving average is $300.01 and its 200-day moving average is $316.20. United Therapeutics Corporation has a 12 month low of $266.98 and a 12 month high of $417.82. The company has a market cap of $13.74 billion, a PE ratio of 12.23, a PEG ratio of 6.68 and a beta of 0.53.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share for the quarter, topping the consensus estimate of $6.29 by $0.34. The firm had revenue of $794.40 million for the quarter, compared to analyst estimates of $726.82 million. United Therapeutics had a return on equity of 19.33% and a net margin of 40.44%. The business's quarterly revenue was up 17.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $6.17 EPS. As a group, equities research analysts expect that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Analysts Set New Price Targets

UTHR has been the subject of a number of analyst reports. Morgan Stanley lowered their target price on shares of United Therapeutics from $348.00 to $328.00 and set an "equal weight" rating for the company in a report on Thursday, July 10th. Cantor Fitzgerald assumed coverage on shares of United Therapeutics in a report on Monday, June 2nd. They issued an "overweight" rating and a $405.00 price target for the company. JPMorgan Chase & Co. decreased their price target on shares of United Therapeutics from $350.00 to $330.00 and set an "overweight" rating for the company in a report on Tuesday, July 8th. Wall Street Zen lowered shares of United Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Friday, May 2nd. Finally, HC Wainwright reissued a "buy" rating and issued a $425.00 price target on shares of United Therapeutics in a report on Monday, May 5th. Four research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat, United Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus target price of $383.08.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of UTHR. Anchor Investment Management LLC boosted its holdings in shares of United Therapeutics by 12.0% during the 4th quarter. Anchor Investment Management LLC now owns 280 shares of the biotechnology company's stock worth $99,000 after buying an additional 30 shares during the period. HB Wealth Management LLC boosted its holdings in shares of United Therapeutics by 2.9% during the second quarter. HB Wealth Management LLC now owns 1,235 shares of the biotechnology company's stock worth $355,000 after acquiring an additional 35 shares during the period. Hohimer Wealth Management LLC grew its position in shares of United Therapeutics by 0.3% in the first quarter. Hohimer Wealth Management LLC now owns 12,651 shares of the biotechnology company's stock valued at $3,900,000 after purchasing an additional 37 shares during the last quarter. Park Avenue Securities LLC increased its stake in shares of United Therapeutics by 1.7% during the second quarter. Park Avenue Securities LLC now owns 2,353 shares of the biotechnology company's stock worth $676,000 after purchasing an additional 39 shares during the period. Finally, Applied Finance Capital Management LLC lifted its holdings in United Therapeutics by 3.7% during the 1st quarter. Applied Finance Capital Management LLC now owns 1,132 shares of the biotechnology company's stock worth $349,000 after purchasing an additional 40 shares during the last quarter. 94.08% of the stock is currently owned by institutional investors and hedge funds.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.